BIO From The Editor and Guest Columns

  1. People: The Most Persistent Risk To Data Integrity
    11/15/2019

    In modern times, the business operating model is commonly referred to by the three resources of “people, process, and technology.” Business intelligence (BI) activities also frequently refer to the triangulation of “people, process, and technology.” And the triad of “people, process, and technology” is touted by organization change management (CM) pundits and business process management (BPM) experts alike.

  2. Early-Stage Biopharma Funding Advice From A Leading VC
    11/13/2019

    5AM Ventures Senior Associate Jason Ruth, Ph.D. dished some insider advice to biotech fund seekers in the Pittsburgh LifeX Labs community, and BioProcess Online was there to catch his talk. Here are the highlights.

  3. Pigeons In The Plant: 10 Real-Life Pharma Facility Blunders (And How To Avoid Them)
    11/13/2019

    There are many ways to tackle pharmaceutical facility design, engineering, building, and production, and each plant has its own methods and culture. However, there are situations we have come across where we really scratch our heads and say, “What did they just do, and what were they thinking?” This article describes a series of events or activities that we have seen and, while they are amusing or baffling, they reveal the flaws in our industry.

  4. How The Medical Innovation Act Could Stifle Medical Innovation
    11/12/2019

    The reincarnated bill targeting big pharma is exemplary of congressional inefficiency and over-legislation. Instead, congress should get better at negotiating and appropriating settlements in the existing system.

  5. SOP Remediation: When Reinventing The Wheel Is The Best Approach
    11/12/2019

    There is a growing industry focus on standard operating procedure (SOP) remediation. Although outsourcing, mergers, and acquisitions have been in play for the last 20 years, these activities seem to be skyrocketing, which is creating quite a few scenarios that drive the need for SOP remediation.

  6. What Can We Learn From Compounding Pharmacies Producing Small Parenteral Batches?
    11/11/2019

    Does the pharmaceutical industry want to sit on the sidelines while its products are being manipulated and modified — a danger? Or will the industry provide its products in a manner or with the tools that will enable compounding pharmacies to succeed in delivering a safe and effective drug to the patient — an opportunity?

  7. 4 Tips For Successful Collaboration With Your EU Qualified Person (QP)
    11/8/2019

    Qualified Persons (QPs) are responsible for the certification of clinical trial materials in the EU and therefore are an essential link in U.S. sponsors’ supply chains. Indeed, engaging QPs well before the clinical trial material needs to be certified not only assures a smooth release process and trial start-up but mitigates pitfalls associated with unanticipated technical, quality, and regulatory challenges.

  8. Debunking The Top 3 Myths About Quality By Design (QbD)
    11/8/2019

    Pharmaceutical quality by design (QbD) and quality risk management (QRM) principles have become mainstays in pharmaceutical development. However, several myths are prevalent that prevent wider acceptance of the concepts by smaller firms. The lack of understanding of pertinent quality by design methods prevents smaller firms from benefiting from the majority of what QbD offers.

  9. New EMA Requirements On Nitrosamines: What ALL Pharma Needs To Know
    11/6/2019

    The EMA recently issued two new publications containing information on nitrosamines for marketing authorization holders (MAHs). Every MAH and manufacturer of chemically synthesized APIs and resulting drug products should carefully read the new EMA expectations on potential nitrosamine contamination.

  10. Will Authorized Biologics Disrupt The Market For Biosimilars?
    11/5/2019

    Many of the doomsday scenario predictions for biosimilar competition if authorized biologics were to enter the space prematurely assume mainstream development and adoption of authorized biologics by innovator companies in the current market and do not take into consideration the outcomes seen over the past 18 years with authorized small molecule generics.